GlassScriptPhysician profile
Laura Miller
NPI 1740570308
$10,458.01
in general payments reported to CMS, 2019-2025
18 companies · $2,695 in 2025
The $2,695 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.33 · 2022: $160 · 2023: $315 · 2024: $7,241 · 2025: $2,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,013 · Travel and Lodging: $2,232 · Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,012.80 |
| Travel and Lodging | $2,232.44 |
| Food and Beverage | $1,005.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,037.63 | 2023-2025 | |
| Axonics, INC. | $1,743.82 | 2023-2024 | Axonics, Bulkamid |
| Astrazeneca Pharmaceuticals LP | $121.82 | 2023 | Tezspire |
| Daiichi Sankyo INC. | $81.72 | 2023-2024 | Injectafer |
| Abbvie INC. | $66.09 | 2021-2024 | |
| Coopersurgical, INC. | $61.86 | 2022 | |
| Pfizer INC. | $51.72 | 2024-2025 | |
| Boston Scientific Corporation | $50.11 | 2025 | Solyx Sis System, General - Female Sui |
| Astellas Pharma US INC | $46.98 | 2024-2025 | Veozah |
| Organon LLC | $28.80 | 2024 | |
| Supernus Pharmaceuticals, INC. | $28.27 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $26.00 | 2022-2023 | M-M-R II, Vaxelis, Vaxneuvance |
| Kowa Pharmaceuticals America, INC. | $24.49 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $21.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.02 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $16.36 | 2021 | |
| Glaxosmithkline, LLC. | $15.37 | 2025 | Bexsero, Rotarix, Pediarix |
| Smith+Nephew, INC. | $14.05 | 2024 | Pico |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.